In September 2022, Eisai Co. and Biogen Inc. announced very positive topline results from the clinical trial of Lecanemab, an investigational treatment for mild cognitive impairment due to Alzheimer’s disease and mild Alzheimer’s Disease. Eisai will be presenting the complete Clarity AD results at this year’s Clinical Trials on Alzheimer’s Congress (CTAD) in San Francisco CA. on November 29, 2022.